Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrogen peroxide topical - Aclaris Therapeutics

Next Previous
Drug Profile

Hydrogen peroxide topical - Aclaris Therapeutics

Alternative Names: A-101 - Aclaris; A-101 45%; ESKATA; ESKERIELE; HP-40; HP-45; Oxydol; V-101 - Aclaris

Latest Information Update: 22 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aclaris Therapeutics
  • Developer Aclaris Therapeutics; Cipher Pharmaceuticals
  • Class Antibacterials; Antiseptics; Disinfectants; Peroxides; Skin disorder therapies
  • Mechanism of Action Antioxidants; Free radical stimulants; Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Seborrhoeic keratosis; Warts

Highest Development Phases

  • Phase III Warts
  • No development reported Seborrhoeic keratosis

Most Recent Events

  • 22 Mar 2022 No development reported - Preregistration for Seborrhoeic keratosis in Canada, Norway, Spain, Austria, France, Germany, Netherlands, Ireland, Italy, Portugal, Czech Republic (Topical)
  • 07 May 2020 Aclaris Therapeutics plans to launch hydrogen peroxide (45%) for Warts and hydrogen peroxide (40%) (Topical)
  • 20 Dec 2019 Aclaris Therapeutics completes a phase III trial in Warts in USA (NCT03812510)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top